Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls.
about
Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leakyOsteoimmunology: Major and Costimulatory Pathway Expression Associated with Chronic Inflammatory Induced Bone LossThe synovio-entheseal complex in enthesoarthritis.Adolescent idiopathic scoliosis and osteopenia)Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications.Effect of periodontal surgery on osteoprotegerin levels in gingival crevicular fluid, saliva, and gingival tissues of chronic periodontitis patients.Angiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment.T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritisRole of polyethylene particles in peri-prosthetic osteolysis: A review.Elevated soluble receptor activator of nuclear factor-kappaB ligand and reduced bone mineral density in patients with adolescent idiopathic scoliosisRheumatic diseases: the effects of inflammation on bone.Gingival crevicularfluid osteoprotegerin levels in Indian population.Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study.Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.The immunoreceptor tyrosine-based activation motif (ITAM) -related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints.Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium.Increased receptor activator of nuclear factor κβ ligand/osteoprotegerin ratio exacerbates cartilage destruction in osteoarthritis in vitroRole of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.Regulation of dendritic cell survival and cytokine production by osteoprotegerin.Th17 and Th22 cells in psoriatic arthritis and psoriasisSynovial tissue heterogeneity and peripheral blood biomarkers.Rheumatoid arthritis in the elderly and its relationship with periodontitis: a review.Pharmacology of intra-articular triamcinolone.Non-canonical NF-κB signaling in rheumatoid arthritis: Dr Jekyll and Mr Hyde?The role of stromal cells in inflammatory bone loss.Circulating Levels of Soluble Receptor Activator of NF- κ B Ligand and Matrix Metalloproteinase 3 (and Their Antagonists) in Asian Indian Patients with Ankylosing Spondylitis.Inflammatory cells and bone loss in rheumatoid arthritis.Serum osteoprotegerin concentration is associated with carotid atherosclerotic plaque in patients with rheumatoid arthritis.Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis.Intracellular apoptotic pathways: a potential target for reducing joint damage in rheumatoid arthritis.Mixed effects of caffeic acid phenethyl ester (CAPE) on joint inflammation, bone loss and gastrointestinal inflammation in a murine model of collagen antibody-induced arthritis.Tocotrienols Regulate Bone Loss through Suppression on Osteoclast Differentiation and Activity: A Systematic Review.Decline in hand bone mineral density indicates increased risk of erosive change in early rheumatoid arthritis.Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening.Markers of bone metabolism in eugonadal female patients with beta-thalassemia major.Osteoclast-Associated Receptor (OSCAR) Distribution in the Synovial Tissues of Patients with Active RA and TNF-α and RANKL Regulation of Expression by Osteoclasts In Vitro.The expression of RANKL and OPG in the various grades of osteoarthritic cartilage.Bone erosions in rheumatoid arthritis: recent developments in pathogenesis and therapeutic implications
P2860
Q24793680-7371C67D-6077-4C31-ACF3-46188D899B22Q27008993-2A53A294-4043-49FE-92D3-E64921FA6833Q33360030-64CF926E-6453-4C30-B61F-010C37D8465DQ35146854-67D0C668-FC5E-4E5A-82ED-B938610C59BAQ35165886-AF3C22F1-DE99-42C0-9948-20D47ADA4231Q35178030-8240A0C9-E51F-43BC-A2B9-8DCAB45BC56AQ35220234-CBCBAD3E-E2BB-4866-8E06-CE92C705159CQ35554105-BBDA7418-3E47-466D-AE17-A25F6C866FAFQ35825373-B2C238E2-D8C1-4881-A4B0-E96E51C72767Q36144864-CC5C258C-7CAC-485B-B44B-77490CAE1D7EQ36324975-1A25BA90-6C4A-40B0-8878-6D64E65156CAQ36728407-7C80B569-72F3-4D06-95A8-3F4671658323Q36842216-E66527CE-E12A-4CC9-9957-9BFF0CC92AD2Q36860987-3A408C8E-AB45-4A97-9679-7F8435A12482Q36907683-C4AF9DBA-1A41-4542-98AA-73BBB418ACECQ37207081-AD54C231-3ADA-4805-9ECD-2B1869E0347BQ37288057-C93F295B-CB64-4DFF-9906-D5AE05CDE8F4Q37344527-B8939AB2-F962-4ED2-B378-B82F919BCFA8Q37362936-211BDB7C-0C19-483C-9B94-88547356D628Q37689670-C5FE42E9-211F-422C-8771-86C8B2F8A75EQ37918858-48004A92-5D5F-4336-9EFD-26633A610AF6Q38093215-F34CE362-3FC6-4600-B66D-CF8ABEA956F1Q38211488-19DACD85-41DA-426A-AFB5-DB8AA385E9FCQ38379658-C062025A-BEA7-4131-8A54-623E8B033CC5Q39248512-A7FAB7DD-F4E7-4417-B7DB-498BF4E2CBA6Q41884710-691FA855-C13B-4BE6-9788-E67D123BB8AFQ42549439-D9F83DAE-16B7-4213-854F-6C7F4DBAE467Q44690593-CD6100FC-0AAC-448D-BD36-753B6B173E8CQ47316849-48A3528E-BF8C-44A1-880F-5BD63623BD29Q47375377-FA1D678E-3299-4F98-A972-88288AD7EC60Q48024495-E7A66F64-CD94-4D77-B96B-99CA9645264DQ50142964-2A387D2F-DC82-4020-BC40-5FD575943DCAQ51151290-49FA1727-CCA4-45D8-B7FA-A91469C883F1Q51728955-093913F8-21E2-4548-A8A4-BED644CFA095Q51739253-A73C7F8E-2264-4819-AF2F-438BF3120E6BQ53109365-65F954EA-EE6B-4FB1-BF0C-2F67AEDB1200Q54391375-E18D44CC-04A7-4D54-BA69-3CFCE4935D4CQ58774487-B9759CF2-7C9C-45FF-8928-B1960CE38607
P2860
Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Osteoprotegerin expression in ...... arthritis and normal controls.
@en
Osteoprotegerin expression in ...... arthritis and normal controls.
@nl
type
label
Osteoprotegerin expression in ...... arthritis and normal controls.
@en
Osteoprotegerin expression in ...... arthritis and normal controls.
@nl
prefLabel
Osteoprotegerin expression in ...... arthritis and normal controls.
@en
Osteoprotegerin expression in ...... arthritis and normal controls.
@nl
P2093
P356
P1433
P1476
Osteoprotegerin expression in ...... oarthritis and normal controls
@en
P2093
A Zannetino
D R Haynes
P J Roberts-Thomson
P304
P356
10.1093/RHEUMATOLOGY/KEG047
P577
2003-01-01T00:00:00Z